Enlivex Therapeutics Ltd., a clinical-stage company specializing in macrophage reprogramming immunotherapy, has announced an upcoming presentation of 3-month topline data from its Phase IIa trial evaluating Allocetra™ in patients with moderate to severe knee osteoarthritis. The data will be discussed during a webinar scheduled for August 18, 2025, at 8:00 AM Eastern Time. This trial, identified as ENX-CL-05-001, is a double-blind, randomized, placebo-controlled study focusing on the safety and efficacy of Allocetra™. The study assesses joint pain and function at 3, 6, and 12 months post-injection in comparison to a placebo. To date, 134 patients have completed the 3-month follow-up period, which is the trial's primary timepoint for measuring key endpoints. The presentation aims to provide detailed insights into the interim results and explore potential benefits of expanding the trial's enrollment.